Navigation Links
InterMune Announces Approval of Clinical Trial Authorization for Phase 1b Trial of ITMN-191
Date:9/4/2007

- Phase 1b trial expected to begin in September -

BRISBANE, Calif., Sept. 4 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that the amended Clinical Trial Authorization (CTA) related to the Phase 1b clinical trial of ITMN-191 (Roche-R7227) has been approved by the appropriate European regulatory authorities. InterMune also has received approval from the Ethics Committee of the institutions that will conduct the Phase 1b study. ITMN-191 is an orally available hepatitis C virus (HCV) protease inhibitor in development by InterMune and its partner, Roche.

InterMune expects that the Phase 1b multiple ascending dose (MAD) study will begin this month and expects to announce initial top-line viral kinetic and safety results from the first three dose cohorts of the MAD study in the first quarter of 2008.

Dan Welch, President and Chief Executive Officer of InterMune, said, "InterMune and Roche are pleased to announce that we have successfully secured the required regulatory approvals that enable us to initiate our very important Phase 1b multiple ascending dose study. By amending the Phase 1b protocol, we believe we have enhanced our ability to deliver the most robust Phase 1b results possible which we expect will place us in a stronger position to begin our Phase 2 trials."

In early May, InterMune announced that it would amend the CTA to take into consideration new information on competitive protease inhibitors, in-vitro and preclinical data on ITMN-191 and pharmacokinetic observations from a Phase 1a study that was completed in May of 2007. In that study, a higher than anticipated exposure of ITMN-191 in plasma was observed in subjects dosed with food, suggesting tha
'/>"/>

SOURCE InterMune, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. InterMune Presents Research on ITMN-191 in Hepatitis C at Digestive Disease Week Meeting
2. InterMune Presents Research on ITMN-191 in Hepatitis C at EASL Annual Meeting
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Sygnis Pharma AG announces date for presentation of clinical results
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2008)...ewswire-FirstCall/ --,Pharmaceutical company Pharm... the Phase 3 clinical trial evaluating the long te...tasis has concluded with no serious,adverse events...atment., A total of 123 subjects started treatmen...ects completed the full 12 months of the trial. Of...
(Date:8/19/2008)...- Particle Sciences Inc. has,expanded its Combinat...d,pilot production capabilities with the installat...ing line. The core of the pilot line,comprising a...20T injection,molder, enables the production of hi...ition gives Particle Sciences the ability to go fr...
(Date:8/19/2008)...used to identify molecular,signature of motor neur...-USNewswire/ -- ALS Therapy,Development Institute ...LS,biomarker effort using blood samples collected ...ps. These ongoing projects are part of the,Institu...ression of genes,and proteins, at the onset of, an...
(Date:8/19/2008)...ll/ -- Vical Incorporated,(Nasdaq: VICL ) today a...ska,Institute, a leading European medical universi...se Control (SMI), a governmental expert agency, to...iojector(R) 2000,needle-free injection system (Bio...multivalent preventive DNA vaccine against HIV., ...
Breaking Medicine Technology:12 Month Phase 3 Trial Finds Bronchitol Safe in Bronchiectasis 212 Month Phase 3 Trial Finds Bronchitol Safe in Bronchiectasis 3Particle Sciences Expands Its Combination Product Capabilities 2ALS Therapy Development Institute Partners with Clinical Centers to Establish Pathological Mechanisms of Lou Gehrig's Disease 2ALS Therapy Development Institute Partners with Clinical Centers to Establish Pathological Mechanisms of Lou Gehrig's Disease 3Karolinska Institute to Test Vical's Vaxfectin(R) Adjuvant with Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control 2Karolinska Institute to Test Vical's Vaxfectin(R) Adjuvant with Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control 3Karolinska Institute to Test Vical's Vaxfectin(R) Adjuvant with Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control 4Karolinska Institute to Test Vical's Vaxfectin(R) Adjuvant with Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control 5Many States Still Fall Short in Emergency Preparedness 3A Report 8484 1Many States Still Fall Short in Emergency Preparedness 3A Report 8484 2Many States Still Fall Short in Emergency Preparedness 3A Report 8484 3Many States Still Fall Short in Emergency Preparedness 3A Report 8484 4Rhode Island Hospital to study driving ability of cognitively impaired elders 8483 1NightHawk Radiology Holdings Inc to Speak at Annual JPMorgan Healthcare Conference on January 10 2008 8481 1NightHawk Radiology Holdings Inc to Speak at Annual JPMorgan Healthcare Conference on January 10 2008 8481 2SecureWorks Designated as a Qualified Security Assessor for PCI Audits 8478 1SecureWorks Designated as a Qualified Security Assessor for PCI Audits 8478 2
...ce shortly, CARMIEL, Israel, April 18, 2007 /PRNew.... today announced that it has received,written not...ation,(FDA) that it may initiate a Phase III clini... candidate, prGCD, a proprietary plant,cell expres...GCD),for the treatment of Gaucher Disease, a lyso...
... out of ten patients taking,once-daily Lialda rema...TON, D.C., May 22, 2007 /PRNewswire-FirstCall/ -- ...nsion study (303),presented at the British Society...tland in March 2007 showed Shire plc,s,Lialda(mesa...atients. Today, secondary endpoints of study 303 w...
Other Medicine Technology:Protalix BioTherapeutics, Inc. Receives Approval from the FDA to,Initiate a Phase III Clinical Trial of prGCD 2Protalix BioTherapeutics, Inc. Receives Approval from the FDA to,Initiate a Phase III Clinical Trial of prGCD 3Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 2Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 3Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 4Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 5Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 6Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 7Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 8
(Date:8/21/2008)... New names and fresh websit... UME/GME administration software , ... one45 Software, a leading provider of healthcare ... of Cytiva Software Inc. (CRX:TSX.V), announced to...hcare education administration products., , ,Compl...
(Date:8/20/2008)... NEWTON, Mass., Aug. 20 /PRNewswire/ -- Questex M...o-business media company and owner of,American Spa... and the,International Beauty Shows, the Internati...) and the SPATEC appointment events today announce...stry portals SpaTrade (, http://www.SpaTrade.com ...
(Date:8/20/2008)... Survey Report Is Available at http://ww...Newswire/ -- A new survey released today,documents...re leveraging,health information technology (HIT) ...The survey results highlight the need for many HIT...dization and,interoperability to optimize clinical...
(Date:8/20/2008)...use postponed reproductive onset in teen, adult fe...EDNESDAY, Aug. 20 (HealthDay News) -- Alcoholism i...ccording to a study that compared women,s and men,... age when they had their first child. , The re...ian twins born between 1893-1964 (3,634 female and...
Breaking Medicine News(10 mins):Health News:Cytiva's one45 Software Rebrands Healthcare Education Administration Products 2Health News:Cytiva's one45 Software Rebrands Healthcare Education Administration Products 3Health News:Cytiva's one45 Software Rebrands Healthcare Education Administration Products 4Health News:Questex Acquires Leading Spa Industry Portal and Spa Executive Business Networking Site and Events 2Health News:Questex Acquires Leading Spa Industry Portal and Spa Executive Business Networking Site and Events 3Health News:New Health IT Survey for Care Management Services Shows Opportunities for Integration, Standardization and Innovation 2Health News:New Health IT Survey for Care Management Services Shows Opportunities for Integration, Standardization and Innovation 3Health News:Women's Alcohol Use Tied to Delayed Childbearing 2
...oped by scientists to enable the easy detection of...are two factors which are called for// where cance...archers led by Professor Calum McNeil are engaged ...er markers - proteins or other molecules produced ...
... statement, highlighting the unwillingness of Chin... bird flu outbreaks.// This was stated following a...ath, by Beijing. The deadly avian bird flu virus ...41-year-old factory worker, from the Southeastern ...
...ence of H5N1 bird flu strain in the poultry sample... the deadly bird flu strain // in six villages Mod... of Romania. Early this month five new cases of ... in Buzau County. Bird flu was first detected in D...
... at the UT Southwestern Medical Center has found t... urinary bladder if a woman is coached during labo... presence of a coach does not seem to provide any ...shortening labor. The study is the first of its k...
Other Medicine News:Health News:Coaching In Labor Could Increase Bladder Problems 2
...e (GH) is a monomeric protein produced and stored ...H is released from the pituitary into the bloodstr...trol of hypothalamic somatostatin (SS) and GH-rele...of GH release appears to be regulated by somatosta...
...he most potent glucocorticoid produced by the huma...d with high affinity to corticosteroid-binding glo...lbumin. Cortisol acts on specific intracellular re...ms, including immune function, glucose counter-reg...
...growth factor I (IGF-I or somatomedin C) is a 7.6 ...ts as a potent mitogen of cellular proliferation, ...urface receptors. In the circulation, IGF-I is bou...to regulate the actions of IGF-I by modulating the...
...growth factor I (IGF-I or somatomedin C) is a 7.6 ...ts as a potent mitogen of cellular proliferation, ...urface receptors. In the circulation, IGF-I is bou...to regulate the actions of IGF-I by modulating the...
Medicine Products: